col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

102 Results       Page 1

Elsevier: Journal of Investigative Dermatology
  original article Date Title Authors   All Authors
1 [GO] 2024―Feb―21 Autophagy during Severe Acute Respiratory Syndrome Coronavirus 2 Induced Leukocytoclastic Vasculitis: New Insights Nesrine Brahimi, Vincent Piguet
2 [GO] 2023―Nov―06 3 Hand-foot-vulva pustule After COVID-19 inactive vaccine Y. Xie, B. Yin
3 [GO] 2023―Nov―06 245 A rare case of erythrodermic sarcoidosis with systemic involvement after COVID-19 vaccination B. Lapolla, E. Gordon, O. Adeuyan, C. Schreidah, L. Fahmy, C. Magro, L. Geskin
4 [GO] 2023―Nov―06 49 A pink nodule developed after COVID-19 vaccine C. Li, Y. Feng
5 [GO] 2023―Nov―06 17 New-onset bullous pemphigoid after SARS-CoV-2 infection S. Zhoi
6 [GO] 2023―Aug―12 SARS-CoV-2 induced vasculitic skin lesions are associated with massive spike protein depositions in autophagosomes Andrea Gawaz, Michael Schindler, Elena Hagelauer, Gabriela Blanchard, Simon Riel, Anneli Vollert, et al. (+9)
7 [GO] 2023―Apr―17 691 Visualization of Covid-19 pandemic influence on healthcare routines in dermatology using electronic health record data J. Ryan Wolf, L. Zhang, Y. Xie, A. Pentland, B.T. Pentland
8 [GO] 2023―Apr―17 576 Gender disparities in isotretinoin prescribing patterns for pediatric patients before and during the COVID-19 pandemic A.J. Tan, J. Xia, D. Kroshinsky
9 [GO] 2023―Apr―17 453 Limited effect of reducing pulmonary tuberculosis incidence amid mandatory facial masking for COVID-19 E. Lin, H. Tu, C. Hong
10 [GO] 2023―Apr―17 403 Updated findings from the Global HS COVID-19 Registry H. Naik, R. Alhusayen, S. Guilbault, J. Ingram, M. Lowes, A. Marzano, et al. (+2)
11 [GO] 2023―Apr―17 228 Impact of COVID-19 and PPE measures on occupational skin disease in healthcare workers S. Chawla, M. Chawla, M. Fugger, C. Moore-gillon, R. Watchorn
12 [GO] 2023―Apr―17 227 Immune response and allergenic components of COVID-19 vaccines induced delayed cutaneous reactions C. Tsai, W. Chung, C. Chen
13 [GO] 2023―Apr―17 226 Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by COVID-19 vaccines C. Wang, C. Chen, W. Chung
14 [GO] 2023―Apr―17 222 Severe COVID-19 infection predisposes patients to greater burden of hair loss S. Patel, M. Colavincenzo
15 [GO] 2023―Apr―17 224 Humoral immune response to COVID-19 vaccination in psoriasis patients on biologic therapy is impaired compared to healthy controls H. Puschmann, W. Milz, S. Emmert, R. Panzer
16 [GO] 2023―Apr―17 223 Spectrum changes of pediatric dermatological disorders before and during the COVID-19 pandemic in China: A single national center for children’s health experience Y. Liu, L. Ma
17 [GO] 2023―Apr―17 221 Impact of the COVID-19 surge on phototherapy in Taiwan: Experience from a university hospital C.E. Lan, K. Chu
18 [GO] 2023―Apr―17 220 Dynamic and spatial transcriptional responses in COVID-19-related chilblains M. Tihy, S. Matar, P. Sohier, N. Dupin, S. Aractingi, B. Oulès
19 [GO] 2023―Apr―17 156 COVID-19 vaccine is a risk factor accelerating time to bullous pemphigoid onset A. Pira, F. Mariotti, F. Moro, A. Panebianco, S. Pallotta, B. Didona, G. Di Zenzo
20 [GO] 2023―Apr―17 219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid A. Mesas Fernández, F. Solimani, E. Bodner, M. Carevic-Neri, T. Jakovljevicova, A. Philipp, et al. (+5)
21 [GO] 2023―Apr―17 225 Enhanced TLR7 immunity drives innate protection against SARS-CoV-2 with chilblains as collateral damage. A. Yatim, F. Saidoune, J. Di Domizio, R. Jenelten, A. Joncic, M. Morren, et al. (+3)
22 [GO] 2023―Apr―01 T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris David O. Croitoru, Vincent Piguet
23 [GO] 2023―Jan―28 SARS-CoV-2 vaccination effectiveness in Rituximab-treated patients affected by Pemphigus Vulgaris C. Fenizia, C. Moltrasio, L. Ottobrini, O. Utyro, G. Genovese, C. Vanetti, et al. (+2)
24 [GO] 2022―Nov―18 076 Risk of severe COVID-19 associated with immune-modifying drugs: data from PsoProtect and Global Rheumatology Alliance registries P Study Group, G. Rheumatology Alliance Study Group
25 [GO] 2022―Nov―18 160 Selected psychological stress and cognitive function parameters in patients suffering from COVID-19 induced telogen effluvium K. Tomaszewska, J. Lawniczak, B. Tarkowski, J. Dudek, A. Zalewska-Janowska
26 [GO] 2022―Nov―18 063 Autoimmunity and disease outcomes of COVID-19, lessons from vitiligo patients N. Post, M. Bekkenk, R. Luiten
27 [GO] 2022―Nov―18 073 Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform S. Langan, C. Smith, T. Collaborative
28 [GO] 2022―Nov―18 147 Cutaneous Manifestations on Covid-19 Patients: A Systematic Review M. Trifitriana, R. Mulawarman
29 [GO] 2022―Nov―18 369 Single-cell RNA sequencing analysis of a COVID-19-associated maculopapular rash in a psoriasis patient treated with ustekinumab K. Rindler, M. Drach, L. Shaw, W. Weninger, M. Farlik, C. Jonak, P.M. Brunner
30 [GO] 2022―Nov―18 168 New considerations regarding vesicular rashes associated with SARS-CoV2 infection and Koebner phenomenon A.L. Tatu, T. Nadasdy, F.C. Bujoreanu, E.B. Niculet, L.C. Nwabudike, D. Radaschin
31 [GO] 2022―Aug―24 Monkeypox: Considerations as a New Pandemic Looms Matthew G. Brewer, Stephanie R. Monticelli, Brian M. Ward
32 [GO] 2022―Jul―20 205 COVID-19 complications in vitiligo patients: A multicenter study R. Raiker, S. Salingaros, H. Pakhchanian, M. Helm
33 [GO] 2022―Jul―20 267 Impact of COVID-19 healthcare disruption on delays in melanoma treatment in rural and urban Iowa A. Munjal, M. Fitzhugh, M. Walsh, P. Gorrepati, R. Tripathi, V. Liu, J.G. Powers
34 [GO] 2022―Jul―20 157 Severity of COVID-19 in patients with dermatomyositis: A single center, retrospective observational cohort study J.S. Johnson, A. Nowacki, J. Narang, S. Young, A. Fernandez
35 [GO] 2022―Jul―20 160 Halved incidence of scrub typhus after travel restriction to confine a surge of COVID-19 in Taiwan in 2021 E. Lin, H. Tu, C. Hong
36 [GO] 2022―Jul―20 LB897 The risk of COVID-19 infection in patients with alopecia areata A. Oulee, S. Ahn, S. Shahsavari, A. Martin, J.J. Wu
37 [GO] 2022―Jul―20 270 Impact of COVID-19 infection on hidradenitis suppurativa activity M.E. Torpey, A. Nosrati, K.L. Campton, S.R. Cohen
38 [GO] 2022―Jul―20 168 COVID-19 mRNA vaccine booster cutaneous reactions reported to the AAD/ILDS dermatology registry S. Prasad, D.E. McMahon, A. Tyagi, R. Singh, R. Ali, H.W. Lim, et al. (+5)
39 [GO] 2022―Jul―20 173 Analyzing the impact of COVID-19 on trends in the dermatology literature R. Ali, S. Prasad, R. Singh, L. Abdelrahman, R. Kankaria, S. Singh, et al. (+3)
40 [GO] 2022―Jul―20 395 Utilization of teledermatology services for dermatological diagnoses during the COVID-19 pandemic A. He, T.T. Kim, K. Nguyen
41 [GO] 2022―Jul―20 387 Consumer attitudes, knowledge, and behavior towards aging skin during the COVID-19 pandemic L. Yang, J. Knoll, R.V. Kundu
42 [GO] 2022―Jul―20 357 Skin cancer treatment delays during the COVID-19 pandemic C.B. Lau, K. Yang, C.X. Pan, W.C. Lau, B. Kassamali, V. Nambudiri
43 [GO] 2022―Jul―20 347 Patient interest in Mohs surgery telehealth services beyond the COVID-19 pandemic A. Munjal, R. Tripathi
44 [GO] 2022―Jul―20 384 Impact of the COVID-19 pandemic on dermatology visits among older adults and racial and ethnic minorities N. Rizk, M.B. Mathur, J. Ko, A. Chiou, I. de Vere Hunt, S. van Egmond, E. Linos
45 [GO] 2022―Jul―20 LB1032 Influence of the covid-19 pandemic on emergency room usage for dermatologic ailments S. Gotewal, A. Good, M. Wilkerson
46 [GO] 2022―Jul―20 LB955 Adherence in dermatology during the COVID-19 pandemic: A review S.G. Bridgeman, P.O. Perche, S.R. Feldman
47 [GO] 2022―Jul―20 145 Erythema multiforme in COVID-19 patients and following COVID-19 vaccination F. Etaee, M. Basiri, T. Naguib, S. Daveluy
48 [GO] 2022―Jul―20 422 Keratinocyte media differences uncovered during COVID-19 supply shortages E.M. Pope, M.C. Moran, M.G. Brewer, L.A. Beck
49 [GO] 2022―Jul―20 359 Public sunscreen dispenser distribution in the United States: Continued COVID-19 trends during 2021 M.D. Szeto, R. Kokoska, J. Maghfour, C. Rundle, C. Presley, T. Harp, et al. (+4)
50 [GO] 2022―Jul―20 366 Comparing patient perspectives towards treatment for alopecia areata before and during COVID-19 using social media data mining J. Jueng, V. Bhupalam, A. Su, C.M. Infante, L. Dupuis, S. Shaikh, et al. (+4)
51 [GO] 2022―Jul―20 265 Evaluating the safety and effectiveness of the COVID-19 vaccination among pediatric atopic dermatitis patients H. Pakhchanian, R. Raiker, K. Jenkins, L. Shen
52 [GO] 2022―Jul―20 260 Responses following COVID-19 vaccination in patients with autoimmune skin disease G. Sprow, M. Afarideh, J. Dan, E. Keyes, M. Grinnell, J. Concha, et al. (+4)
53 [GO] 2022―Jul―20 262 Safety and efficacy of the COVID-19 vaccine among fully vaccinated and boosted skin cancer patients R. Raiker, H. Pakhchanian, M. Deng
54 [GO] 2022―Jul―20 149 Proposing a standardized assessment of COVID-19 vaccine cutaneous reactions R. Singh, R. Ali, S. Prasad, K. Blumenthal, E. Freeman
55 [GO] 2022―Jul―20 LB926 COVID-19 vaccine hesitancy in a cohort of hidradenitis suppurativa patients M. Torpey, A. Nosrati, K.L. Campton, S. Cohen
56 [GO] 2022―Jul―20 LB923 COVID-19 vaccine immunity in hidradenitis suppurativa patients receiving TNF-alpha inhibitors A. Nosrati, M.E. Torpey, G.D. Ball, N. Shokrian, K.L. Campton, S.R. Cohen
57 [GO] 2022―Jul―20 322 Is social media spreading misinformation on the COVID-19 vaccines within the psoriasis community? D. Yee, C. Zagona-Prizio, S. Khan, S. Khan, N. Maynard, M.D. Mehta, et al. (+2)
58 [GO] 2022―Jul―20 LB1043 COVID-19-associated pruritus is non-histaminergic mediated A. Labib, L.A. Nattkemper, A. Vander Does, T. Ju, S. Cacciapuoti, M. Vastarella, et al. (+2)
59 [GO] 2022―Jul―20 801 Experience of advanced dermatology and cosmetic surgery clinics providers with teledermatology amidst the coronavirus disease-19 lockdown C.M. Infante, J. Jueng, A. Su, B. Maner, T. Harding, S. Eubanks, J. Solomon
60 [GO] 2022―Jul―20 LB981 Pandemic associated chilblain-like lesions result from an inducible type 1 interferon response to SARS-CoV-2 L. Arkin, A. Costa da Silva, J. Mays
61 [GO] 2022―Jul―20 850 Potential role of skin in SARS-CoV-2 infection D. Chudakova, A. Klopot, B. Shi, P. Bhalla, L.C. Tsoi, B.E. Perez White, I. Budunova
62 [GO] 2022―Jul―20 389 Impact of the COVID19 pandemic on the execution of real world, pragmatic trials: The LITE study experience B. Hefele, K. Duffin, L. Howard, D.B. Shin, J.M. Gelfand
63 [GO] 2021―Oct―08 067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases T. Hillary, A. Van Laethem, F. Castelijns, S. Vermeire, J. Geldof, M. Ferrante, et al. (+6)
64 [GO] 2021―Oct―08 072 Covid-19 and male androgenetic alopecia: Systematic investigation of a potential epidemiological and genetic association S.K. Henne, L.M. Hochfeld, C. Maj, M.M. Nöthen, S. Heilmann-Heimbach
65 [GO] 2021―Oct―08 065 Application of teledermatology during the first wave of the COVID-19 pandemic in Hungary A. Jobbágy, F. Meznerics, K. Farkas, S. Bozsányi, L. Fesus, N. Kiss, et al. (+4)
66 [GO] 2021―Oct―08 055 The impact of methotrexate and targeted immunosuppression on cellular and humoral immune responses to COVID-19 vaccine BNT162b2: a cohort study S.K. Mahil, K. Bechman, A. Raharja, C. Domingo-Vila, M. Brown, A. Cope, et al. (+9)
67 [GO] 2021―Oct―08 245 Demodex folliculorum interaction with SARS-CoV2 from a chitin-lipid perspective A.L. Tatu, T. Nadasdy, F.C. Bujoreanu, D. Radaschin, L.C. Nwabudike
68 [GO] 2021―Aug―19 LB761 Clinical outcomes in Pemphigoid and Pemphigus patients with COVID-19 H. Pakhchanian, R. Raiker, J. Wang, K. Phan
69 [GO] 2021―Aug―19 LB751 COVID-19 complications in patients with Hidradenitis Suppurativa: A multicenter study R. Raiker, H. Pakhchanian, K. Phan
70 [GO] 2021―Aug―19 LB767 A multicenter analysis of patients using telemedicine for dermatological conditions during the COVID-19 pandemic R. Raiker, H. Pakhchanian, M. Baker, E. Hochman, M. Deng
71 [GO] 2021―Aug―19 LB723 Face skin changes caused by face mask during the COVID-19 pandemic S. Park, J. Han, Y. Yeong, N. Kang, B. SUH, E. Kim
72 [GO] 2021―Aug―19 LB768 Adult and pediatric emergency department visits for dermatological conditions during the COVID-19 pandemic: A multicenter analysis H. Pakhchanian, R. Raiker, K. Russomanno, M. Deng
73 [GO] 2021―Aug―19 LB771 Racial and Ethnic Disparities in COVID-19-Related Infection in Patients with Psoriasis: A Cross-Sectional Study C. Nguyen, S. Shwe, K. Yale, A. Ghigi, K. Zheng, N. Mesinkovska, T. Bhutani
74 [GO] 2021―Aug―19 LB740 SARS-CoV-2-associated ‘covid toes:’ multiplex immunofluorescent characterization of pathophysiology J.J. Moon, A. Costa da Silva, J.M. Tran, C. Kim, R. Sharma, M. Hinshaw, et al. (+7)
75 [GO] 2021―Aug―04 Assessing the risk and outcome of COVID-19 in patients with psoriasis or psoriatic arthritis on biologic treatment: a critical appraisal of the quality of the published evidence Stefano Piaserico, Paolo Gisondi, Simone Cazzaniga, Sara Di Leo, Luigi Naldi
76 [GO] 2021―Jul―15 From your nose to your toes: A Review of SARS-CoV-2 Pandemic-associated Pernio Lisa M. Arkin, John J. Moon, Jennifer M. Tran, Samira Asgari, Cliona O’Farrelly, Jean-Laurent Casanova, et al. (+4)
77 [GO] 2021―Apr―19 255 The risk of contracting COVID-19 after dermatological procedures compared with other medical procedures R. Raiker, H. Pakhchanian, A. Baghdjian, V.A. Patel
78 [GO] 2021―Apr―19 336 Risks of COVID-19 infection and mortality for patients on biologics V. Pahalyants, W. Murphy, N. Klebanov, N. Theodosakis, M. Klevens, E. Lilly, et al. (+2)
79 [GO] 2021―Apr―19 028 Use of systemic immunosuppressive treatment is not related to COVID-19 infection in a retrospective review of patients in Massachusetts W. Murphy, N. Klebanov, V. Pahalyants, N. Theodosakis, K. Patel, M. Klevens, et al. (+2)
80 [GO] 2021―Apr―19 316 The impact of COVID-19 on gender representation in academic dermatology publications M.D. Szeto, M. Laughter, M.B. Maymone, T.E. Sivesind, C.L. Presley, S.M. Lada, et al. (+2)
81 [GO] 2021―Apr―19 652 Using implementation science to understand teledermatology during the COVID-19 pandemic S. Briggs, J. Lipoff, S. Collier
82 [GO] 2021―Apr―19 391 Public sunscreen dispensers and consumer sunscreen trends during the COVID-19 pandemic J. Maghfour, C. Rundle, M.D. Szeto, C.L. Presley, C. Eason, C. Dunnick, et al. (+2)
83 [GO] 2021―Apr―19 281 Racial and language disparities in teledermatology visits for acne during the COVID-19 pandemic M.S. Lee, B. Kassamali, N. Shah, A. Lachance, V. Nambudiri
84 [GO] 2021―Apr―19 461 A review of cutaneous lymphoma outcomes during COVID-19 pandemic at Columbia University T. Garcia-Saleem, C. Stonesifer, L. Geskin
85 [GO] 2021―Apr―19 433 Increased risk of hospital acquired sacral pressure injuries in COVID-19 patients J. Narang, J. Gallop, S. Seck, A.H. Wei, A.S. Nowacki, A.P. Fernandez
86 [GO] 2021―Apr―19 441 Cutaneous findings in COVID-19 patients hospitalized at a large urban academic medical center S. Chand, R. Rrapi, J. Lo, C. Gabel, S. Song, Z. Holcomb, et al. (+9)
87 [GO] 2021―Apr―19 342 Clinical outcomes in COVID-19 patients with Atopic dermatitis H. Pakhchanian, R. Raiker, V.A. Patel
88 [GO] 2021―Apr―19 338 Clinical outcomes in COVID-19 patients with dermatopolymyositis H. Pakhchanian, R. Raiker, A. Qureshi, V.A. Patel
89 [GO] 2021―Apr―19 243 Clinical outcomes in COVID-19 patients with varicella zoster virus R. Raiker, H. Pakhchanian, A. Gonzalez Lopez, V.A. Patel
90 [GO] 2021―Apr―19 011 Systemic hyperinflammation as a driver of maculopapular drug exanthema in severely ill COVID-19 patients? Y. Mitamura, D. Schulz, I. Kolm, S. Oro, M. Levesque, E. Maverakis, et al. (+2)
91 [GO] 2021―Apr―19 254 COVID-19 related outcomes in psoriasis and psoriasis arthritis patients R. Raiker, H. Pakhchanian, V.A. Patel
92 [GO] 2021―Apr―19 032 A multicomponent skin-targeted COVID-19 vaccine elicits robust humoral and cellular immune responses S.C. Balmert, Z.G. Ghozloujeh, C.D. Carey, T.L. Sumpter, G. Erdos, E. Korkmaz, L.D. Falo
93 [GO] 2021―Apr―19 381 Perspective of psoriatic disease patients on novel COVID-19 vaccines G. Gondo, S. Heydon, S. Bell
94 [GO] 2021―Apr―19 205 Evaluation of SARS-CoV-2 spike protein response on PI3K agonist-mediated IL-8 release C.E. Borchers, A. Thyagarajan, C. Rapp, J.B. Travers, R. Sahu
95 [GO] 2021―Apr―19 332 National trends of dermatology procedures during the COVID pandemic R. Raiker, H. Pakhchanian, K. Alam, A. Hakopian, V.A. Patel
96 [GO] 2021―Apr―19 335 Trends in dermatological prescribing patterns during the COVID pandemic H. Pakhchanian, R. Raiker, K. Alam, A. Hou, V.A. Patel
97 [GO] 2021―Apr―19 331 Trends and outcomes in patients with malignant skin cancers during the COVID pandemic R. Raiker, H. Pakhchanian, A. Hussain, M. Deng
98 [GO] 2021―Apr―19 677 Personal protective equipment needs during the COVID-19 pandemic: A survey of medical dermatologists S. Chand, R. Rrapi, C. Gabel, Y. Levin, V. Neel, D. Kroshinsky
99 [GO] 2020―Oct―15 ACE2 expression on the keratinocytes and SARS-CoV-2 percutaneous transmission, are they related? Ruixuan Zhu, Yaqian Shi, Yixin Tan, Rong Xiao
100 [GO] 2020―Sep―02 Clinical research post COVID-19: Embracing a new normal Joel M. Gelfand, Brooke E. Hefele
101 [GO] 2020―Aug―14 The Impact of Covid-19 on Dermatology Clinical Trials Sheena Desai, Priya Manjaly, Karen Lee, Sara J. Li, Cyriac Manjaly, Arash Mostaghimi
102 [GO] 2020―May―23 High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2 Xiaotong Xue, Zihao Mi, Zhenzhen Wang, Zheng Pang, Hong Liu, Furen Zhang

102 Results       Page 1


Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.015 sec